Illumina Valuation
Is ILU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ILU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ILU (€134.82) is trading below our estimate of fair value (€150.8)
Significantly Below Fair Value: ILU is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ILU?
Key metric: As ILU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ILU's PS Ratio? | |
|---|---|
| PS Ratio | 5.1x |
| Sales | US$4.39b |
| Market Cap | US$22.23b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.5x |
| Enterprise Value/EBITDA | 32.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ILU's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
SRT3 Sartorius | 4.4x | 9.3% | €13.4b |
1SXP SCHOTT Pharma KGaA | 4.2x | 10.7% | €4.0b |
GXI Gerresheimer | 1.3x | 10.2% | €2.6b |
EVT Evotec | 1.9x | 12.1% | €1.5b |
ILU Illumina | 5.1x | 4.8% | €22.2b |
Price-To-Sales vs Peers: ILU is expensive based on its Price-To-Sales Ratio (5.1x) compared to the peer average (3x).
Price to Sales Ratio vs Industry
How does ILU's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ILU is expensive based on its Price-To-Sales Ratio (5.1x) compared to the European Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is ILU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.1x |
| Fair PS Ratio | 4.4x |
Price-To-Sales vs Fair Ratio: ILU is expensive based on its Price-To-Sales Ratio (5.1x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €134.82 | €156.17 +15.8% | 16.1% | €241.00 | €113.86 | n/a | 25 |
| Nov ’25 | €137.78 | €144.38 +4.8% | 19.0% | €231.69 | €96.54 | n/a | 24 |
| Oct ’25 | €116.02 | €134.26 +15.7% | 20.2% | €226.72 | €94.47 | n/a | 23 |
| Sep ’25 | €118.44 | €133.35 +12.6% | 19.3% | €217.51 | €94.37 | n/a | 23 |
| Aug ’25 | €112.94 | €135.97 +20.4% | 22.3% | €223.46 | €92.34 | n/a | 22 |
| Jul ’25 | €97.72 | €137.50 +40.7% | 22.3% | €225.91 | €93.35 | n/a | 22 |
| Jun ’25 | €92.68 | €142.91 +54.2% | 23.8% | €232.51 | €91.90 | n/a | 22 |
| May ’25 | €115.34 | €147.50 +27.9% | 23.0% | €237.52 | €93.88 | n/a | 23 |
| Apr ’25 | €126.88 | €147.62 +16.3% | 23.4% | €238.03 | €78.42 | n/a | 22 |
| Mar ’25 | €129.18 | €147.40 +14.1% | 23.4% | €238.08 | €78.44 | n/a | 22 |
| Feb ’25 | €133.66 | €142.46 +6.6% | 29.8% | €238.21 | €73.86 | n/a | 24 |
| Jan ’25 | €127.68 | €135.04 +5.8% | 32.4% | €233.70 | €45.29 | n/a | 24 |
| Dec ’24 | €99.99 | €141.37 +41.4% | 38.1% | €239.69 | €46.10 | n/a | 21 |
| Nov ’24 | €100.08 | €185.69 +85.5% | 24.0% | €300.22 | €94.41 | €137.78 | 21 |
| Oct ’24 | €129.78 | €200.90 +54.8% | 25.4% | €300.80 | €94.59 | €116.02 | 21 |
| Sep ’24 | €155.82 | €205.60 +31.9% | 19.2% | €293.10 | €138.26 | €118.44 | 21 |
| Aug ’24 | €172.56 | €214.38 +24.2% | 17.7% | €292.12 | €133.59 | €112.94 | 20 |
| Jul ’24 | €170.98 | €224.40 +31.2% | 17.5% | €307.84 | €137.43 | €97.72 | 19 |
| Jun ’24 | €184.84 | €224.65 +21.5% | 17.7% | €308.92 | €137.91 | €92.68 | 19 |
| May ’24 | €185.68 | €223.10 +20.2% | 17.5% | €304.44 | €136.73 | €115.34 | 19 |
| Apr ’24 | €213.75 | €225.47 +5.5% | 16.2% | €279.36 | €139.68 | €126.88 | 20 |
| Mar ’24 | €186.68 | €226.95 +21.6% | 16.8% | €282.09 | €139.65 | €129.18 | 20 |
| Feb ’24 | €196.26 | €229.12 +16.7% | 16.2% | €275.97 | €147.18 | €133.66 | 20 |
| Jan ’24 | €185.52 | €241.69 +30.3% | 19.4% | €330.19 | €150.94 | €127.68 | 18 |
| Dec ’23 | €207.55 | €249.18 +20.1% | 19.3% | €338.03 | €154.53 | €99.99 | 16 |
| Nov ’23 | €234.10 | €263.17 +12.4% | 18.9% | €344.15 | €177.14 | €100.08 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
5.1%
1Y
22.9%